Fig 1: In Vivo Validation of EP300 Regulating SLC16A1-AS1/TCF3-Mediated Wnt/β-Catenin Pathway Impact on LC Malignancy. A: RT-qPCR, assessing the transfection efficiency of co-overexpressing SLC16A1-AS1 in H1299 cells with EP300 knockdown. B–D: In vivo tumor growth model, evaluating the in vivo growth capability and tumor weight of H1299 cells subjected to different treatments. E–F: Western blot (WB) measured the nuclear accumulation of β-catenin in the collected tumor masses. All cell experiments were independently repeated three times, and each group of animal experiments involved 5 mice. A Paired t-test (A) was used for comparisons between two groups, while Two-way ANOVA (B, D, F) was applied for comparisons involving multiple groups. Tukey's post-hoc test was used. *P < 0.05.
Fig 2: EP-300/H3K27ac axis mediates the SLC16A1-AS1 promoter to induce its transcription. A, enrichments of H3K27ac modifications and EP300 near the SLC16A1-AS1 predicted using the UCSC browser; B, binding between EP300 and SLC16A1-AS1 promoter examined by the ChIP-qPCR assay; C-D, expression of EP300 mRNA (C) and SLC16A1-AS1 in H1299 and Calu-3 cells after the administration of sh-EP300 examined by RT-qPCR; E, enrichment of H3K27ac near the SLC16A1-AS1 promoter in H1299 and Calu-3 cells overexpressing EP300 examined by ChIP-qPCR. Three biological replicates were performed. Differences were analyzed by the two-way ANOVA. *p < 0.05.
from Cell Signaling Technology for SimpleChIP ® Human EP300 Promoter Primers